title: Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
abstract: OBJECTIVE
  To investigate patient satisfaction with antimuscarinic treatment of overactive bladder syndrome, and to identify factors having a significant influence on satisfaction.
  
  
  METHODS
  A cross-sectional questionnaire survey was carried out to assess treatment satisfaction among male and female patients with overactive bladder (age ≥20 years) in the Hokuriku district of Japan. The overactive bladder symptom scores, treatment efficacies, adverse events (dry mouth and constipation), and patient satisfaction scores were investigated and compared among patients using different antimuscarinic therapeutics.
  
  
  RESULTS
  In total, 977 survey respondents (52.6% men; mean age 73.6 years) received antimuscarinic treatment. The mean overactive bladder symptom score of these patients was 6.17; in addition, 32.3% patients were satisfied with their treatment, but 33.1% were dissatisfied. Factors having a significant influence on treatment satisfaction were sex (men were less satisfied), efficacy, adverse events and the overactive bladder symptom score. Constipation negatively influenced patient satisfaction to a greater extent than did dry mouth. Patient satisfaction varied according to the drug used. Constipation was less severe with the immediate-release-type agents (imidafenacin and oxybutynin) than with the extended-release-type (propiverine, solifenacin or tolterodine).
  
  
  CONCLUSIONS
  Just one-third of Japanese Hokuriku patients with overactive bladder seem to be satisfied with their antimuscarinic treatment. Patient satisfaction is impaired by poor efficacy and the presence of adverse events; furthermore, constipation should be recognized as an adverse event that negatively influences patient satisfaction to a greater extent than dry mouth. Patient satisfaction differs according to the antimuscarinic agent used, with higher patient satisfaction being associated with less severe constipation.
authors.affiliation: Department of Urology, Faculty of Medical Science, University of Fukui, Eiheiji, Fukui, Japan.
authors.forename: Hironobu
authors.initials: H
authors.lastname: Akino
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hideki
authors.initials: H
authors.lastname: Fuse
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Katsuhito
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Fujiuchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokoyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D001561:Benzilates / Q000008:administration & dosage / Q000009:adverse effects; D003408:Cresols / Q000008:administration & dosage* / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007564:Japan; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D017060:Patient Satisfaction; D010665:Phenylpropanolamine / Q000008:administration & dosage* / Q000009:adverse effects*; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D001561:Benzilates; D003408:Cresols; D007093:Imidazoles; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D010665:Phenylpropanolamine; C015586:propiverine; D000068737:Tolterodine Tartrate; C005419:oxybutynin; D000069464:Solifenacin Succinate; C120953:imidafenacin
keywords: antimuscarinic agent; constipation; imidafenacin; overactive bladder; satisfaction